These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 8513651)

  • 1. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.
    Lindsay CA; Bosso JA
    Clin Pharmacokinet; 1993 Jun; 24(6):496-506. PubMed ID: 8513651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.
    Touw DJ; Vinks AA; Mouton JW; Horrevorts AM
    Clin Pharmacokinet; 1998 Dec; 35(6):437-59. PubMed ID: 9884816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles.
    Klutman NE
    Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
    Zabner R; Quinn JP
    Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.
    de Groot R; Smith AL
    Clin Pharmacokinet; 1987 Oct; 13(4):228-53. PubMed ID: 3311531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the new quinolones in cystic fibrosis.
    Grenier B
    Rev Infect Dis; 1989; 11 Suppl 5():S1245-52. PubMed ID: 2672252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.
    Sörgel F; Stephan U; Wiesemann HG; Gottschalk B; Stehr C; Rey M; Böwing HB; Dominick HC; Geldmacher von Mallinckrodt M
    Infection; 1987; 15(5):385-96. PubMed ID: 3319914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
    Zobell JT; Young DC; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Jun; 48(6):525-37. PubMed ID: 23359557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Beta-lactam antibiotics.
    Lietman PS
    Chest; 1988 Aug; 94(2 Suppl):115S-120S. PubMed ID: 3293936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics.
    Horrevorts AM; Driessen OM; Michel MF; Kerrebijn KF
    Chest; 1988 Aug; 94(2 Suppl):120S-125S. PubMed ID: 3293937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of pharmacokinetics and pharmacodynamics: does the dose matter?
    MacGowan AP
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S238-9. PubMed ID: 11524725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.
    Touw DJ
    Pharm World Sci; 1998 Aug; 20(4):149-60. PubMed ID: 9762727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of antibiotics in cystic fibrosis.
    Akkerman-Nijland AM; Akkerman OW; Grasmeijer F; Hagedoorn P; Frijlink HW; Rottier BL; Koppelman GH; Touw DJ
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):53-68. PubMed ID: 33213220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review.
    Castagnola E; Cangemi G; Mesini A; Castellani C; Martelli A; Cattaneo D; Mattioli F
    Int J Antimicrob Agents; 2021 Sep; 58(3):106381. PubMed ID: 34157401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro effect of various antibiotics: beta lactams, aminoglycosides and fluoroquinolones alone and in combination against P. aeruginosa isolated from patients with mucoviscidosis].
    Croize J; Gout JP; Robert J; Le Noc P
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):573-7. PubMed ID: 2508041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the pharmacotherapy of cystic fibrosis.
    Bosso JA
    J Clin Pharm Ther; 1992 Oct; 17(5):263-70. PubMed ID: 1464631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.
    Meyers BR; Wilkinson P
    Clin Pharmacokinet; 1989 Dec; 17(6):385-95. PubMed ID: 2689039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic therapy of pulmonary infections in cystic fibrosis. Dosage schedules and duration of treatment.
    Strandvik B
    Chest; 1988 Aug; 94(2 Suppl):146S-149S. PubMed ID: 3396437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.
    Bearden DT; Rodvold KA
    Clin Pharmacokinet; 2000 May; 38(5):415-26. PubMed ID: 10843460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.